Home / Sell-Side M&A / Healthcare IT & Services M&A Advisory
Windsor Drake advises healthcare IT and tech-enabled healthcare services founders on the sale of their companies through institutional-grade competitive processes. The firm combines direct knowledge of how PE-backed healthcare IT consolidators, strategic health IT platform companies, health systems and payor technology arms, enterprise software vendors entering healthcare, healthcare services companies productizing into technology, and public healthcare IT companies seeking growth acquisitions evaluate reimbursement model exposure, EHR integration architecture, HIPAA compliance maturity, clinical workflow depth, and the tech-enabled versus labor-intensive positioning that determines whether a company is valued on software multiples or services multiples with sector-specific valuation methodologies to position companies for optimal outcomes across revenue cycle management, electronic health records and practice management, patient engagement, clinical decision support and analytics, telehealth, healthcare data and interoperability, and healthcare workforce technology platforms.
Healthcare IT and services M&A advisory is sell-side investment banking for companies that sell technology and tech-enabled services to healthcare providers, payors, and health systems. The category spans revenue cycle management software and services that optimize billing, coding, claims processing, and payment collection, electronic health records and practice management platforms that serve as the clinical and administrative backbone for healthcare practices, patient engagement and digital front door platforms that manage scheduling, intake, communication, and patient experience, clinical decision support and analytics platforms that improve care quality and operational performance, telehealth and virtual care platforms that deliver remote clinical services, healthcare data and interoperability platforms that enable data exchange across fragmented healthcare systems, and healthcare workforce management and staffing technology that addresses the industry’s persistent labor challenges. It requires fluency in both B2B SaaS transaction dynamics and the reimbursement model exposure, HIPAA compliance, EHR integration depth, and clinical workflow dependencies that make healthcare fundamentally different from other technology verticals.
Healthcare IT M&A is being reshaped by a structural investor pivot. PE firms are systematically shifting capital away from reimbursement-exposed provider models toward software and services platforms that support care delivery without direct reimbursement risk. Capital invested in B2B healthcare IT rose 11% year-over-year in 2024 to $14.7 billion, with deal count increasing 36%. Healthcare IT M&A activity rose 26% in 2025. The consolidation thesis is clear: acquirers are building integrated technology platforms that combine RCM automation, EHR functionality, patient engagement, and analytics into unified offerings — and they are paying materially different multiples for tech-enabled platforms versus labor-intensive services companies. Francisco Partners acquired AdvancedMD for $1.1 billion. GE HealthCare acquired Intelerad for $2.3 billion. EQT acquired GeBBS for $850 million. The pattern favors companies positioned on the technology side of the spectrum.
Windsor Drake combines institutional sell-side process discipline with direct knowledge of healthcare IT buyer behavior, reimbursement model assessment, HIPAA compliance documentation, EHR integration evaluation, and the tech-enabled versus labor-intensive positioning framework that drives valuation in healthcare IT and services transactions.
The most consequential positioning decision in healthcare IT M&A is where the company sits on the tech-enabled versus labor-intensive spectrum. Tech-enabled platforms — those where software automates clinical or administrative workflows, AI replaces manual labor, and recurring SaaS subscriptions generate 70%+ gross margins — command 12–20x+ EBITDA because they represent scalable infrastructure. Labor-intensive services companies — those where revenue scales linearly with headcount, margins depend on labor arbitrage (often offshore), and customer relationships depend on individual account managers — trade at 3–8x EBITDA. The critical positioning question is not what the company does but how it delivers value: through software that scales without proportional labor, or through people performing work that software could eventually replace. PE firms are systematically repricing this distinction, and the gap between software-margin and services-margin healthcare IT businesses has widened to 2–3x on the same revenue base.
Founders 12 to 18 months from a potential transaction benefit from early assessment through Windsor Drake’s exit readiness practice. Pre-transaction preparation includes HIPAA compliance audit, EHR integration depth assessment, reimbursement model exposure analysis, revenue quality documentation (recurring SaaS vs. services vs. implementation), payor and provider customer concentration review, AI integration positioning, and buyer universe construction.
Windsor Drake runs a milestone-based process calibrated to the specific dynamics of healthcare IT transactions — including tech-enabled versus labor-intensive positioning, HIPAA compliance documentation, EHR integration assessment, reimbursement model exposure analysis, and the regulatory and clinical workflow dependencies that determine how acquirers model healthcare technology businesses.
Deep analysis of revenue composition and recurring revenue quality (SaaS subscriptions versus implementation and professional services versus transaction-based fees versus percentage-of-collections models), gross margin architecture (software-margin versus blended technology-and-services-margin versus labor-intensive-services-margin — the single most scrutinized metric in healthcare IT M&A), customer segmentation (ambulatory practices by specialty and size, health systems, hospitals, payors, post-acute providers — each with different switching costs and contract dynamics), reimbursement model exposure assessment (does the company’s revenue depend directly or indirectly on Medicare, Medicaid, or commercial payor reimbursement rates — and what happens to revenue if reimbursement policies change), EHR integration architecture (depth and breadth of integrations with Epic, Cerner/Oracle Health, Meditech, athenahealth, eClinicalWorks, NextGen — integration depth determines implementation velocity and switching costs), HIPAA compliance and security program maturity (SOC 2 Type II, HITRUST certification, penetration testing history, breach history, BAA coverage), clinical workflow depth (how deeply the platform embeds in daily clinical operations — shallow tools face replacement risk, deep workflow integration creates structural retention), AI and automation capabilities (ambient clinical documentation, automated coding, predictive analytics, prior authorization automation — AI is the primary value creation driver in 2026), specialty vertical concentration, and interoperability standards compliance (HL7, FHIR, CDA). Development of the positioning thesis framing the company on the tech-enabled spectrum.
Identification and qualification of PE-backed healthcare IT consolidators building integrated platforms through systematic add-on acquisition (the most active buyer category — firms with existing portfolio companies in RCM, EHR, practice management, or patient engagement seeking complementary capabilities to build comprehensive healthcare technology stacks), strategic healthcare IT platform companies acquiring capabilities to fill product suite gaps (Waystar, athenahealth, AdvancedMD, NextGen, eClinicalWorks, Greenway Health, CareCloud, Veradigm), health system and payor technology arms seeking to build or buy technology capabilities (often acquiring point solutions to embed in their provider or member ecosystems), enterprise software companies entering the healthcare vertical (Salesforce Health Cloud, ServiceNow, Oracle Health), healthcare services companies productizing manual processes into software-enabled delivery (offshore RCM companies acquiring AI-powered automation to transform labor-intensive models into tech-enabled platforms), and public healthcare IT companies seeking growth acquisitions to satisfy investor expectations (Waystar, Evolent, Phreesia, Veeva). Each buyer evaluated on platform architecture, specialty vertical alignment, customer base overlap, integration requirements, and specific acquisition thesis.
Direct, confidential outreach to 50–100+ qualified buyers. All conversations gated behind non-disclosure agreements. Healthcare IT transactions carry heightened confidentiality requirements — provider customer lists include healthcare organizations subject to HIPAA, clinical workflow details may reveal protected health information handling practices, and a provider client discovering its technology vendor is in a sale process raises data security continuity and HIPAA compliance concerns that directly affect contract renewals. Information released in stages with protections for customer identity, pricing architecture, clinical workflow specifics, and PHI handling details.
Receipt and evaluation of indications of interest. Healthcare IT-specific negotiation considerations — whether valuation applies on an EBITDA multiple, ARR multiple, or revenue multiple basis (pure SaaS companies valued on ARR multiples, blended tech-and-services companies on EBITDA, labor-intensive services on EBITDA at lower ranges), the treatment of professional services and implementation revenue, percentage-of-collections revenue classification and sustainability analysis, BAA assignment and HIPAA compliance transfer mechanics, EHR integration maintenance commitments post-close, clinical workflow team retention provisions (implementation specialists, clinical informaticists, specialty-specific domain experts), and the treatment of pending regulatory certifications and payor contracts. Earnout structures tied to ARR or revenue growth milestones, customer retention thresholds, AI automation deployment targets, and specialty vertical expansion metrics — calibrated to the healthcare procurement cycle where enterprise sales often close in Q4 for January implementation.
Coordination across financial, technical, regulatory, and compliance workstreams. Healthcare-specific diligence includes HIPAA compliance review (security risk assessment documentation, BAA inventory and coverage, breach incident history and response, workforce training records, physical and technical safeguards, audit log capabilities), HITRUST or SOC 2 Type II certification review, product architecture assessment (multi-tenant SaaS architecture, EHR integration depth and methodology, FHIR and HL7 interoperability compliance, data encryption at rest and in transit), reimbursement model exposure analysis (revenue sensitivity to Medicare and Medicaid rate changes, commercial payor contract dependencies, regulatory policy risk assessment), gross margin decomposition (isolating software revenue margins from services revenue margins to demonstrate the tech-enabled component), customer contract review (BAA terms, contract assignability, data portability obligations, termination provisions tied to ownership change), ARR quality analysis with cohort-level retention segmented by provider specialty and size, AI capabilities validation (clinical accuracy metrics, bias testing, regulatory positioning), clinical workflow team assessment, and competitive positioning. The advisor manages the data room and resolves compliance findings before they become deal impediments.
Negotiation of the purchase agreement, including BAA assignment and HIPAA compliance transfer, PHI data handling and security program continuity obligations, clinical workflow team retention and employment transition, EHR integration maintenance commitments (provider customers depend on integrations with Epic, Cerner, and other EHR platforms that require ongoing certification and API maintenance), customer contract assignment and provider notification mechanics, product continuity and roadmap commitments, AI model documentation and responsible AI representations, regulatory certification maintenance (ONC certification, state-specific healthcare IT requirements), payor contract portability, and representations regarding data security incident history and ongoing compliance program investment. Coordination with legal counsel through signing and closing, including post-closing integration timelines, platform consolidation roadmaps, and provider communication sequencing — healthcare IT transitions must not disrupt clinical operations or compromise patient data security.
Ready to discuss a potential healthcare IT transaction?
Windsor Drake advises a limited number of healthcare IT companies each year.
A company reporting 55% blended gross margins without decomposing the components leaves buyers to assume the worst. If those margins combine 80% SaaS subscription margins with 25% professional services margins, the SaaS component is a premium asset masked by a services drag. If those margins are 55% across the board from a single revenue stream, the company is a tech-enabled services business valued differently. Pre-process preparation must include a gross margin decomposition by revenue line — SaaS subscriptions, implementation services, transaction fees, managed services, percentage-of-collections — showing each component’s margin, growth trajectory, and relative weight. The goal is to isolate and highlight the highest-margin revenue to demonstrate the company’s position on the tech-enabled spectrum.
Every healthcare IT buyer’s first question is how revenue is affected by reimbursement policy changes. A company that does not proactively address reimbursement exposure in its positioning materials cedes the narrative to the buyer’s risk committee. The positioning thesis must explicitly categorize the company’s reimbursement relationship: directly exposed (revenue scales with reimbursement rates), indirectly exposed (customer financial health depends on reimbursement), or insulated (revenue driven by compliance, efficiency, or workforce needs independent of payment rates). For companies with direct exposure — particularly percentage-of-collections RCM models — the thesis must demonstrate resilience: historical revenue stability through prior reimbursement changes, contractual floors, diversified payor mix, and the counter-cyclical argument that providers invest more in RCM optimization when margins compress.
HIPAA compliance in healthcare IT diligence goes far beyond confirming the existence of a privacy policy. Buyers conduct deep compliance audits: the security risk assessment must be current, comprehensive, and documented with remediation tracking. Every customer relationship must be covered by a Business Associate Agreement with terms that survive assignment. Any breach history must be fully documented with incident response records. Encryption standards, access controls, audit logging, and workforce training must be provable. A company that treats HIPAA as a checkbox — maintaining minimal documentation, operating with incomplete BAA coverage, or having never completed a formal risk assessment — faces diligence findings that create escrow holdbacks, indemnification carve-outs, and valuation reductions. HITRUST certification eliminates most compliance diligence friction and signals institutional-grade security maturity.
AI is the primary valuation driver in healthcare IT — and the most overstated capability. Every company claims AI in 2026. Buyers now demand production metrics: how many encounters, claims, or clinical events are processed by AI versus manual labor, what accuracy rates does the AI achieve in production (not in testing), what measurable labor reduction has been achieved for customers using AI features, and what is the AI revenue contribution (customers paying specifically for AI-powered capabilities versus AI embedded in base pricing). A company claiming AI-powered coding without documenting production accuracy rates, volume processed, and measurable coder labor reduction will be discounted to services-level multiples regardless of its marketing language. Pre-process preparation should include an AI capabilities dossier with production metrics, accuracy benchmarks, and documented customer outcomes.
The healthcare IT buyer universe extends beyond other health IT vendors. Health systems are building technology capabilities internally or through acquisition. Payors are acquiring technology that improves provider performance and reduces claims friction. Enterprise software companies (Salesforce, ServiceNow, Oracle) are entering healthcare. Cybersecurity companies are addressing healthcare-specific security needs. Fintech companies are solving healthcare payments and revenue cycle problems. Offshore BPO companies are acquiring AI technology to transform their labor models. Each buyer category values different aspects of the company, and competitive tension across categories drives auction dynamics that narrow processes miss.
EHR integrations are not implementation costs — they are structural switching costs. A platform that has achieved deep integration with a provider’s Epic environment — certified through App Orchard, embedded in clinical workflows, exchanging bidirectional data through FHIR APIs, triggering automated actions within the EHR — has created a switching cost that extends beyond the platform itself. Replacing the platform means disconnecting integrations that clinical staff depend on daily, recertifying new integrations that take months, and disrupting workflows during a transition period that providers will not tolerate. The pre-process documentation should include the EHR integration matrix showing every customer’s EHR platform, integration depth, certification status, and the operational impact of disconnection — transforming what appears to be a technical detail into a quantified retention asset.
A specialty-focused RCM software and analytics platform serving orthopedic and physical therapy practices with $11.5M in ARR, 116% net revenue retention, and approximately 340 practice customers across 22 states engaged an M&A advisor to explore strategic alternatives. The platform combined automated coding (AI-powered medical coding achieving 94% first-pass accuracy in production across 2.1 million encounters annually), claims management, denial prevention analytics, and practice benchmarking into a single SaaS platform. Gross margins were 74% on the SaaS subscription component, with blended margins of 62% including implementation services. The company held HITRUST certification, maintained BAAs with all customers, and had no breach history. Deep integrations with athenahealth, NextGen, and eClinicalWorks — including certified marketplace listings — served as structural switching costs. The average practice customer had been on the platform for 3.6 years, with gross retention of 96%.
The advisor positioned the company on three value layers: the AI-powered coding automation as a labor-replacement asset — 94% first-pass accuracy in production with documented 40% reduction in coding staff hours for customers using the automated workflow, positioning the technology as a margin expansion engine for any acquirer, the specialty-specific RCM intelligence (orthopedic and PT-specific billing rules, denial patterns, and benchmarking data from 340 practices creating a proprietary dataset that generic RCM platforms cannot replicate), and the EHR-integrated SaaS delivery model with 74% software gross margins demonstrating that this is a technology platform, not a services company. The buyer universe included 60+ qualified parties: a PE-backed healthcare IT consolidator building an integrated specialty practice management platform, a large RCM services company seeking AI technology to transform its labor-intensive offshore model, a specialty EHR vendor filling the RCM gap in its practice management suite, a healthcare analytics company expanding from hospital-level analytics to ambulatory practice intelligence, and a PE firm building a musculoskeletal-focused healthcare platform.
Competitive tension between the RCM services company — which valued the AI coding automation as a transformative technology that could convert its 30% gross margin services business into a 60%+ tech-enabled model — and the PE-backed consolidator — which valued the 340-practice specialty footprint and the proprietary orthopedic/PT benchmarking dataset — drove the final multiple above initial indications. The pre-documented gross margin decomposition (isolating 74% SaaS margins from blended), AI production metrics dossier (94% first-pass accuracy, 2.1M encounters processed, 40% coding labor reduction), HITRUST certification, EHR integration matrix with marketplace certifications, and cohort-level retention analysis eliminated the margin quality, AI validation, compliance, switching cost, and retention risks that create late-stage friction. The deal included a cash-at-close component, ARR growth and AI adoption earnouts at 12 and 24 months, clinical domain team retention packages, and EHR integration maintenance commitments. Process from engagement to signing: approximately eight months.
US healthcare spending exceeds $4.8 trillion annually and is growing faster than GDP — a structural tailwind for healthcare IT that does not exist in other technology verticals. Healthcare IT M&A activity rose 26% in 2025 with over 400 health tech deals, driven by PE capital pivoting from reimbursement-exposed provider models toward technology platforms. Capital invested in B2B healthcare IT reached $14.7 billion in 2024. Digital health funding rose 19% to $22.3 billion in 2025. The consolidation is accelerating — Francisco Partners acquired AdvancedMD for $1.1 billion, GE HealthCare acquired Intelerad for $2.3 billion, EQT acquired GeBBS for $850 million, Qualtrics is acquiring Press Ganey for $6.75 billion — and the consolidation thesis is consistent: integrated technology platforms that automate clinical and administrative workflows command premium multiples.
Healthcare IT companies are valued on a wider spectrum than most B2B SaaS verticals. The spread between tech-enabled platforms (12–20x+ EBITDA with software gross margins) and labor-intensive services companies (3–8x EBITDA with services gross margins) is the defining valuation dynamic. A fintech company is valued on transaction volume and regulatory licensing. A cybersecurity company is valued on detection efficacy and platform extensibility. A healthcare IT company is valued on gross margin architecture, reimbursement model exposure, EHR integration depth, clinical workflow embedding, AI automation capabilities, HIPAA compliance maturity, and specialty vertical concentration — and which side of the tech-enabled versus labor-intensive divide the company falls on determines a 2–3x multiple difference on the same EBITDA base.
The deal mechanics are healthcare-specific. BAA assignment and HIPAA compliance transfer, PHI data handling continuity obligations, EHR integration certification maintenance, ONC regulatory compliance, clinical workflow team retention, payor contract portability, and representations regarding breach history and security program investment create closing workstreams that do not exist in EdTech, payments, or horizontal SaaS transactions.
Six buyer categories: PE-backed healthcare IT consolidators building integrated platforms through systematic add-on acquisition (the most active buyer category — firms with existing portfolio companies seeking RCM, EHR, patient engagement, analytics, and workforce technology capabilities to build comprehensive stacks), strategic healthcare IT platform companies acquiring to fill product gaps (Waystar, athenahealth, AdvancedMD, NextGen, eClinicalWorks, Greenway, CareCloud, Veradigm), health system and payor technology arms building or buying capabilities (embedding technology into their provider or member ecosystems), enterprise software companies entering healthcare (Salesforce Health Cloud, ServiceNow, Oracle Health, Workday), healthcare services companies productizing labor into technology (offshore RCM companies acquiring AI automation to transform business models), and public healthcare IT companies seeking growth acquisitions (Waystar, Evolent, Phreesia, Veeva).
Windsor Drake advises on healthcare IT transactions between the United States and Canada. Cross-border execution requires navigation of different healthcare regulatory frameworks — US HIPAA versus Canadian PIPEDA and provincial health privacy legislation (PHIPA in Ontario, HIA in Alberta), different EHR ecosystems (Epic and Cerner dominate US hospital market; Canada has a more fragmented landscape with provincial health information exchanges), and different reimbursement models (US multi-payor versus Canadian single-payor provincial systems). Healthcare IT platforms serving cross-border customers must support both regulatory environments with jurisdiction-specific compliance, interoperability, and data residency configurations.
Healthcare IT M&A advisory is sell-side investment banking for companies that sell technology and tech-enabled services to healthcare providers, payors, and health systems. The advisor represents the founder in a structured sale process, building a buyer universe that spans PE-backed healthcare IT consolidators, strategic platform companies, health system technology arms, enterprise software vendors, healthcare services companies productizing into technology, and public healthcare IT companies, while managing tech-enabled versus labor-intensive positioning, HIPAA compliance documentation, EHR integration assessment, reimbursement model exposure analysis, and the clinical workflow dependencies unique to healthcare IT transactions.
Healthcare IT companies are valued on EBITDA multiples ranging from 4–20x+, with the wide range reflecting the structural divide between tech-enabled platforms and labor-intensive services. Pure SaaS platforms with 70%+ gross margins, AI automation capabilities, and deep EHR integrations command 12–20x+ EBITDA. Tech-enabled services companies with blended gross margins of 40–60% trade at 8–12x. Labor-intensive services companies with services-level margins trade at 3–8x. Key premium drivers include gross margin architecture, AI-driven labor replacement metrics, EHR integration depth, HIPAA compliance maturity (HITRUST certification), specialty vertical concentration, reimbursement insulation, and customer retention above 95%.
Gross margin reveals the fundamental nature of a healthcare IT business better than any other metric. It tells buyers whether the company is a software platform (70–85% margins that scale without proportional labor), a tech-enabled services business (40–60% margins with a software-plus-labor delivery model), or a labor-intensive services company (20–35% margins that scale linearly with headcount). This distinction directly determines the EBITDA multiple — software-margin companies are valued 2–3x higher than services-margin companies on the same EBITDA base. The gross margin decomposition by revenue line is the first analysis buyers perform.
Windsor Drake advises across seven healthcare IT domains: Revenue Cycle Management (RCM) software and services, Electronic Health Records (EHR) and practice management, patient engagement and digital front door platforms, clinical decision support and analytics, telehealth and virtual care, healthcare data and interoperability, and workforce management and staffing technology.
Six buyer categories: PE-backed healthcare IT consolidators building integrated platforms (most active category), strategic healthcare IT platform companies filling product gaps (Waystar, athenahealth, AdvancedMD, NextGen, Greenway), health system and payor technology arms, enterprise software companies entering healthcare (Salesforce Health Cloud, ServiceNow, Oracle Health), healthcare services companies acquiring technology to transform labor-intensive models, and public healthcare IT companies seeking growth acquisitions.
AI is the primary valuation driver in healthcare IT for 2026. Acquirers model AI through a labor-replacement lens — every manual process automated converts services-margin revenue into software-margin revenue, simultaneously expanding gross margins and increasing the EBITDA multiple. Companies that demonstrate production AI metrics (automated coding accuracy rates, measurable staff hour reductions, claims processed without human intervention) command premiums because buyers model AI-driven margin expansion as post-acquisition value creation. Companies claiming AI without production metrics are discounted to services-level multiples. Ambient clinical documentation, automated coding, prior authorization automation, and predictive denial prevention are the highest-value AI capabilities.
Windsor Drake advises healthcare IT and tech-enabled healthcare services companies with $3M–$50M in revenue, typically generating $1M–$10M in EBITDA. This range spans companies with documented provider or payor customer relationships, HIPAA compliance programs, recurring or contractual revenue, and product-market fit sufficient for institutional-grade acquirers.
The optimal engagement window is 12 to 18 months before a target transaction date. Healthcare IT transactions require pre-transaction preparation including HIPAA compliance audit and remediation (pursuing HITRUST certification if not already held), EHR integration depth assessment and documentation, gross margin decomposition by revenue line, reimbursement model exposure analysis, AI capabilities documentation with production metrics, customer retention analysis segmented by provider specialty and size, clinical workflow team retention planning, and buyer universe construction with specific platform gap analysis per acquirer.
Windsor Drake advises a limited number of healthcare IT and tech-enabled services companies each year. If you are a founder considering a sale or recapitalization in the next 12–18 months, a confidential discussion is the appropriate first step.
All inquiries are strictly confidential. No information is disclosed without written consent.
Sell-side M&A advisory for founders.
©2026 Windsor Drake